Table 1 COVID-19 profile and response measures in selected locations
Indicators | Chile | Hong Kong | India | New Zealand | South Korea | South Africa | United Kingdom | United States | |
|---|---|---|---|---|---|---|---|---|---|
Demographics | Population total | 19,212,362 | 7,552,800 | 1,393,409,033 | 5,126,300 | 51,305,184 | 60,041,996 | 68,207,114 | 332,915,074 |
Over 65 years of age (%) | 11 | 16 | 6.0 | 15 | 14 | 5.3 | 19 | 15 | |
Epidemiology | Daily cases (per million) | 1,021 | 4,316 | 5.4 | 4,702 | 4,273 | 27 | 1,459 | 141 |
Positivity rate (%) | 28 | 0.15 | 1.2 | 26 | 32 | 7.7 | 5.3 | 5.3 | |
COVID-19 deaths (per million) | 8.0 | 33 | 0.16 | 0 | 1.9 | 0.3 | 3.9 | 5.1 | |
Excess mortality (%) | 18.19 | 2.99 | NA | -3.74 | 1.16 | 22.94 | 10.24 | 16.07 | |
Utilization of healthcare resource | Hospitalization (cases per million) | NA | 932 (ref. 21) | NA | 79 (ref. 22) | 1.7 (ref. 23) | 39 (ref. 24) | 155 | 118 |
ICU cases | 1,079 | 60 (ref. 21) | NA | 10 (ref. 22) | 715 | 247 (ref. 24) | 290 | 7,547 | |
Vaccination | Vaccination coverage, initial course (%) | 89.6 | 68.8 | 56.8 | 77.3 | 86.5 | 28.8 | 71.9 | 64.7 |
Booster policy (offered to all adults unless otherwise specified) | Second booster (February 2022) | First booster (December 2021) | First booster only for HCWs, HRGs and people over 60 years of age (January 2022) | First booster (3 months after initial course) (February 2022) | Second booster for HRGs only (February 2022) | First booster (Febraruy 2022) | Second booster only for HCWs, HRGs and people over 75 years of age (March 2022; autumn 2022 booster planned) | First booster (November 2021) | |
Vaccination for children (types, eligible age) | CoronaVac (children over 3 years of age) | BNT162b2 (children over 3 years of age) | BBV152 (children 15–18 years of age; those 5–15 years of age, under consideration) | BNT162b2 (children over 5 years of age) | BNT162b2 (children over 5 years of age) | BNT162b2 (children over 12 years of age) | BNT162b2 (children 5–12 years of age, and HRGs) Booster (children over 12 years of age (in England, Ireland and Wales) and HRGs (in Scotland)) | BNT162b2 (children over 5 years of age; those 6 months to 4 years of age, under consideration) | |
Access to antivirals | Ritonavir-boosted nirmatrelvir (courses) | Excluded from licensing deal | ≤3,000 (estimate) | Needs local clinical trials | 60,000 | 31,000 | Awaiting approval | 2.75 million | 20 million |
Molnupiravir (courses) | NA | ≤3,000 (estimate) | Approved | 60,000 | Awaiting approval | Approved but not purchased | 2.23 million | 3.1 million | |
Current key public health measures | Testing | Antigen tests not widely available | Planning a compulsory universal testing | Antigen tests available in the private sector | Free antigen tests available when required | Prioritizing high-risk populations | Public testing free of charge | Free lateral flow and PCR test to cease on 1 April 2022 (England); limited tests available for HCWs and HRGs | Every household eligible to order four free tests |
Masking | Mandated | Mandated | Mandated but declining adherence | Mandated | Mandated | Mandated; loosening restrictions | No longer mandated | Lifted in many states | |
Restrictions | Mobility pass required for interstate trips | Small curbs possible | Full vaccination required for entry into public places in some states | Opening schools and workplaces | Quarantine imposed on international travelers | Reopening schools | ‘Living with COVID’ plans being implemented | Loosening in many states | |
